Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Andorra Health Watch.
Press releases published on July 17, 2025

欧州アレルギー・臨床免疫学会 (EAACI) リーダー陣、2025年大会の記録的成功を振り返る:アレルギーおよび免疫学における転機
チューリッヒ発, July 17, 2025 (GLOBE NEWSWIRE) -- 7,600人以上の参加者を迎えた2025年欧州アレルギー・臨床免疫学会 (EAACI Congress 2025) は、その規模の大きさだけでなく、同学会のリーダー陣が発信した力強いメッセージによって注目を集めた。 開催から1か月が経過した今、グラスゴーでの学会を終えた欧州アレルギー・臨床免疫学会の主要人物たちは、この出来事を「分野における転換点」と表現し、その所感を共有している。 同学会は6月13日から16 …

EAACI 지도부, 알레르기 및 면역학의 중대한 순간 맞이한 역사적인 2025 총회를 되돌아보다
취리히, July 17, 2025 (GLOBE NEWSWIRE) -- 7,600명 이상의 대표단이 참석한 유럽 알레르기 임상 면역학회(EAACI) 2025 행사가 규모 뿐만 아니라 고위 관계자들이 전달한 강력한 메시지로 더욱 화제를 모았다. 글래스고에서 총회 폐막이 있은 지 한 달이 지난 지금, EAACI의 주요 인사들이 이 분야의 전환점이라고 할 수 있는 총회에 대한 소회를 공유하고 있는 것이다. 6월 13일부터 16일까지 스코틀랜드 이벤트 캠퍼스 ( …

Pemimpin EAACI Mengimbas Kembali Persidangan 2025 yang Mencatat Sejarah: Saat Penting untuk Alergi dan Imunologi
ZURICH, July 17, 2025 (GLOBE NEWSWIRE) -- Dengan kehadiran lebih 7,600 delegasi, Kongres EAACI 2025 mencuri perhatian bukan sahaja kerana skala penganjurannya, tetapi juga mesej berimpak tinggi yang disampaikan oleh pihak kepimpinan. Kini, sebulan selepas …

Liderança da EAACI reflete sobre o Congresso Recorde de 2025: um momento crucial para as áreas de Alergia e Imunologia
ZURIQUE, July 17, 2025 (GLOBE NEWSWIRE) -- Com mais de 7.600 delegados presentes, o Congresso da EAACI 2025 foi manchete não apenas por sua magnitude, mas pela mensagem poderosa transmitida por sua liderança. Agora, um mês após a conclusão do Congresso em …




Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories
€7.5 million upfront, with total potential development and commercial milestones, depending on Denali trial results, of up to €191.5 million Tiered royalties of up to 20% in the U.S., starting at a minimum of 8%, with tiered high single to double digit …

Nicox et Kowa signent un accord clé pouvant atteindre jusqu’à 191,5 millions d’euros pour les droits exclusifs du traitement du glaucome NCX 470 aux Etats-Unis et dans l’ensemble des territoires non-licenciés
17 juillet 2025 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), une société internationale spécialisée en ophtalmologie, annonce aujourd’hui la signature d’un nouvel accord majeur …

Press Release: Sanofi announces extension of Blueprint tender offer
Sanofi announces extension of Blueprint tender offer Paris, July 17, 2025. Sanofi today announces that Rothko Merger Sub, Inc., a wholly owned subsidiary of Sanofi, has extended the expiration date of its tender offer to purchase all of the outstanding …

Communiqué de presse : Sanofi annonce la prolongation de l’offre publique d’achat sur Blueprint
Sanofi annonce la prolongation de l’offre publique d’achat sur Blueprint Paris, le 17 juillet 2025. Sanofi annonce aujourd'hui que Rothko Merger Sub, Inc., une filiale détenue à 100 % par Sanofi, a prolongé la date d'expiration de son offre publique d' …

VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC
ZURICH, SWITZERLAND, July 17, 2025 -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting …